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Background
BNP has emerged as a potent antifibrotic peptide inhibiting
collagen production, augmenting matrix metalloprotein-
ases, and suppressing proliferation in cardiac fibroblasts [1].
Particulate guanylate cyclase natriuretic peptide receptor A
(NPR-A), to which BNP binds, shares structural (receptor
dimerization and short unique cytoplasmic tails) and
sequence (RGD motif binding DDX domains) similarities to
integrin receptors and like integrins NPR-A may transduce
signals from the extracellular matrix (ECM). Recently, we
reported evidence for outside-inside signaling where by
fibronectin (FN), an extracellular matrix protein, augments
the increase in cGMP production by BNP in cultured human
CFs plated on FN and is also augmented by a Mayo designed
RGD peptide based upon an NPR-A sequence. It is reported
that integrin receptor subtypes can regulate TGF beta binding
to the TGB beta-receptor providing evidence for integrin –
TGF beta-receptor cross-talk. In view of these observations,
we hypothesized that potential cross-talk may exist between
NPR-A and integrin receptors in human CFs.
Methods
Human CFs were cultured as previously described. CFs were
pre-incubated in HBSS containing Hepes, BSA, and IBMX for
10 minutes then treated with BNP (10-6 M) with or without
antibodies to three integrin receptors that include antibodies
to alpha-v-beta-3, beta-8 and beta-3 integrin receptors. Cyclic
GMP was measured as described previously.
Results
The alpha-v-beta-3 antibody had no effect on basal cGMP
generation. In contrast, BNP markedly increased cGMP gen-
eration in CFs (P < 0.05). Importantly, integrin alpha-v-beta-
3 antibody further augmented BNP stimulated cGMP gener-
ation (120%, P=.0295), as did integrin subunit antibody
beta-8 (145%, P = 0.0002), and integrin subunit antibody
beta-3 (150%, P = 0.02).
Conclusion
These studies provide new insight into the biology of partic-
ulate guanylate cyclase and integrin receptors in response to
BNP stimulation in human CFs. Specifically, antibodies to
integrin receptors augment BNP activation of cGMP in CFs.
The mechanism of this augmentation remains undefined
but may imply that integrin receptors interact directly with
NPR-A to alter NPR-A sensitivity to BNP warranting further
studies. The current observations suggest cross-talk between
these two receptor types that play a key role in control of
myocardial structure.
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